TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04272437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
Study: NCT02974907
Drug: RGN-259
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Study: NCT02974907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study: NCT02331511
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administration for 3 months after device(PPM,ICD,CRT) implantation
Study: NCT01430533
Drug: Vehicle pre foam formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02420353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
Study: NCT01293097
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study: NCT00471510
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Normalized name: tetrapeptide-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
Study: NCT03169816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for lorcaserin condition dosed twice daily
Study: NCT03499873
Drug: Nepafenac 0.3% Oph Susp
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.3% Ophthalmic suspension (experimental product)
Study: NCT03499873
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03499873
Drug: Nepafenac 0.3% Oph Susp (reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.3% Ophthalmic suspension (Innovator)
Study: NCT03630627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously
Study: NCT01652898
Drug: LDLA202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study: NCT04275115
Drug: Drug Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)
Study: NCT01166113
Drug: Pomalidomide, Cyclophosphamide, Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d
Study: NCT01929278
Drug: CT Gel (clindamycin 1% and tretinoin 0.025%)
Normalized name: tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
Study: NCT01143337
Drug: MP-435(dose1) + Methotrexate
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP-435 dose1 + stable weekly dose of Methotrexate
Study: NCT01143337
Drug: Placebo + Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + stable weekly dose of Methotrexate
Study: NCT02761915
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02294305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT01828203
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01828203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04371224
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NaliCap
Study: NCT04371224
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NAPOLI
Study: NCT01345539
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
Study: NCT00983996
Drug: Fosamax Tablets, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, single-dose fasting
Study: NCT01493180
Drug: OPC-12759 ophthalmic suspension
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-12759 ophthalmic suspension 2%
Study: NCT01045720
Drug: Suo Quan Wan, Wu Lin San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suo Quan Wan Wu Lin San Placebo 2/daily
Study: NCT01045720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch)
Study: NCT00218465
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02674529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03506178
Drug: Normal saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study: NCT02035878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT01261767
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for subcutaneous (under the skin) injection
Study: NCT03205033
Drug: Melatonin 20 MG Oral Capsule
Normalized name: melatonin 20 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day 1 hour before go to bed
Study: NCT03205033
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day 1 hour before go to bed
Study: NCT03385863
Drug: Surfactant, Pulmonary，Curosurf
Approvals — FDA: no, EMA: no, PMDA: no
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
Study: NCT02966028
Drug: SNF472
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Study: NCT02966028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Study: NCT00854477
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
Study: NCT02936570
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)
Study: NCT00102726
Drug: SB497115
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
Study: NCT02721563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
Study: NCT01502904
Drug: pravastatin 20mg/day after DES implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT01502904
Drug: Non-ARB /day after DES implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT01502904
Drug: Eposartan 600mg/day after DES implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT04062175
Drug: Azithromycin Tablets
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
Study: NCT02887885
Drug: Gynoflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
Study: NCT00517998
Drug: Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL Hydrogel
Study: NCT00654498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01401504
Drug: ASP3026
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02795078
Drug: conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03504475
Drug: Paxil® 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
Study: NCT01479517
Drug: Kovacaine Mist 0.1 mL x 4 sprays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
Study: NCT01479517
Drug: Kovacaine Mist 0.2 mL x 2 sprays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
Study: NCT01479517
Drug: Kovacaine Mist 0.2 mL x 1 spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose = 1 intranasal spray of study drug
Study: NCT02038023
Drug: Intravaneous iron(low molecular weight iron dextran)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of Iron dextran administered over one hour
Study: NCT01726933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Study: NCT01456247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Study: NCT02995135
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)
Study: NCT01456247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study: NCT01277835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Infusion at same rate as experimental arm
Study: NCT02965261
Drug: Torrent's Fluoxetine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965261
Drug: Warner Chilcott LLC Sarafem Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
Study: NCT01865331
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT01287351
Drug: extra-fine hydrofluoroalkane beclometasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00095537
Drug: panHer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
Study: NCT03334695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as sterile 0.9% saline for injection.
Study: NCT01994980
Drug: Default 4 days antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
Study: NCT00065962
Drug: secretin, synthetic porcine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02625974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00840840
Drug: Augmentin ES-600™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Study: NCT01253564
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg b.i.d. orally
Study: NCT02990910
Drug: Individualized opioid analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: (a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
Study: NCT00657527
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01315678
Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Study: NCT01315678
Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment
Study: NCT00368576
Drug: SB 480848, tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer Placebo to HCC patients who are indicated for TACE after randomization
Study: NCT00364559
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg 10 days daily
Study: NCT02509286
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
Study: NCT00642993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching SCH 497079 administered orally
Study: NCT03544242
Drug: Pre-Isolation Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
Study: NCT00413127
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo i.v.
Study: NCT01993186
Drug: UX007
Normalized name: UX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral liquid
Study: NCT01993186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral liquid
Study: NCT01513161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00491738
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT05214677
Drug: DW1809
Approvals — FDA: no, EMA: no, PMDA: no
Description: pelubiprofen 30mg
Study: NCT03608917
Drug: Total Glucosides of Paeony(TGP) analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
Study: NCT00273377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02910245
Drug: Mercaptopurine (Purinethol)
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04337658
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT02910245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01975753
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03531060
Drug: IRL790
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRL790 capsule 10 mg
Study: NCT03531060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00042380
Drug: Novasoy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00413959
Drug: VELCADE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Study: NCT00413959
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
Study: NCT02288273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01039675
Drug: 500mcg/25mcg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719/GW642444
Study: NCT01568814
Drug: Low volume PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: low volume polyethylene glycol 2 liter one time
Study: NCT01568814
Drug: high volume PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
Study: NCT01039675
Drug: Placebo once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive, excipients only
Study: NCT01617941
Drug: BGG492
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01617941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
Study: NCT03373604
Drug: 18F-MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Study: NCT00822744
Drug: Placebo (for SSR411298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: capsule~Route: oral administration with food
Study: NCT04512404
Drug: HMG-CoA Reductase Inhibitor
Normalized name: HMG-CoA reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02641730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
Study: NCT01386333
Drug: Saline Nasal Mist
Normalized name: Saline Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts